IDH1 and IDH2 Gene Role in Glioma
Commentary - Volume: 1, Issue: 2, 2026 (January)
Abrar Hussain*

Department of Biological Sciences, International Islamic University, Islamabad, Pakistan

*Correspondence to: Abrar Hussain, Department of Biological Sciences, International Islamic University, Islamabad, Pakistan. E-Mail:
Received: August 18, 2025; Manuscript No: JMBC-25-1396; Editor Assigned: August 20, 2025; PreQc No: JMBC-25-1396(PQ); Reviewed: August 22, 2025; Revised: August 28, 2025; Manuscript No: JMBC-25-1396(R); Published: January 05, 2026

ABSTRACT

Glioma is a type of tumor originating from glial cells in the brain and spinal cord. It primarily affects astrocytes, oligodendrocytes, and ependymal cells. Mutations in the Isocitrate Dehydrogenase 1 (IDH1) and Isocitrate Dehydrogenase 2 (IDH2) genes are pivotal in gliomagenesis, particularly in diffuse lower-grade gliomas and secondary glioblastomas. These mutations, especially at R132 in IDH1 and R172 in IDH2, confer a neomorphic activity converting α-ketoglutarate (α-KG) to D-2-hydroxyglutarate (2-HG). Elevated 2-HG disrupts α-KG–dependent dioxygenases, resulting in genome-wide epigenetic modifications, collectively termed the glioma CpG island methylator phenotype (G-CIMP). Clinically, these mutations correlate with younger age at diagnosis, favorable prognosis, and improved survival. IDH mutations are now essential in the 2021 WHO classification of CNS tumors. Targeted therapies such as ivosidenib, enasidenib, and vorasidenib aim to reverse 2-HG accumulation. This commentary outlines the molecular basis, clinical impact, and therapeutic opportunities related to IDH1/2 mutations in glioma.

Keywords: IDH1, IDH2, glioma, 2-hydroxyglutarate, epigenetic dysregulation, G-CIMP, targeted therapy.


Citation: Hussain A (2026). IDH1 and IDH2 Gene Role in Glioma. J. Mol. Biol. Vol.1 Iss.2, January (2026), pp:7-9.
Copyright: © 2026 Hussain A. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Article Processing Timeline

2-5 Days Initial Quality & Plagiarism Check
15
Days
Peer Review Feedback
85% Acceptance Rate (after peer review)
30-45 Days Total article processing time

Indexed In

Google Scholar
DOAJ
CrossRef
PubMed
MEDLINE
ResearchBib
OAJI
Sindexs
EBSCO A-Z / Host
OCLC - WorldCat

Journal Flyer

Flyer Image

Recommended Journals